THE PERFECTION OF LEGAL REGULATION OF HUMAN GENOME EDITING RESEARCH AND APPLICATION IN CHINA  

我国人类基因组编辑研究和应用的法律规制（英文）

作　　者：Xiao Peng 肖鹏(School of Foreign Studies of Zhongnan University of Economics and Law)

机构地区：[1]School of Foreign Studies of Zhongnan University of Economics and Law

出　　处：《China Legal Science》2019年第6期58-81,共24页中国法学（英文版）

基　　金：supported by the Fundamental Research Funds for the Central Universities,Zhongnan University of Economics and Law(Grant Number:2722019JCT018)

摘　　要：In terms of applied research and clinical practice, human genome editing can be generally divided into somatic genome editing and germline genome editing,in addition to basic research. Genome editing is performed in somatic cells for prevention or treatment of illnesses or disabilities, which is of great benefit to humans and poses relatively small risks. Genome editing is performed in germline cells for prevention or treatment of illnesses or disabilities and genetic enhancement, which is expected to produce great benefits, but may bring about technological, ethical, legal and even social risks and problems.One good example is that the world’s first genetically modified baby twins have aroused considerable controversy around the globe. There are quite a few deficiencies in the legal regulation of human genome editing research and application in China, therefore China needs to clarify the guiding thought,basis and principles of legislation by referring to relevant foreign legislation and considering China’s practicalities, formulate the Human Genome Editing Safety Law, establish and improve the regulatory mechanism as well as pertinent systems, and strengthen legal regulation.人类基因组编辑除基础研究外,在应用研究和临床应用层面大体分为体细胞基因组编辑和生殖系基因组编辑两类。前者用于疾病或残疾治疗/预防,对人类而言风险较小;后者包括疾病或残疾预防/治疗和基因增强,虽预期利益大,但存在技术、伦理、法律乃至社会诸方面的风险和问题,基因编辑婴儿事件在国内外掀起轩然大波即为明证。我国人类基因组编辑研究和应用的法律规制存在诸多不足,亟需借鉴域外相关立法,结合我国实际,明确立法指导思想、根据和原则,制定《人类基因组编辑安全法》以确立监管机制和相关制度,加强法律规制。

关 键 词：立法指导思想 人类基因组 基因组编辑 法律规制 预期利益 基因编辑 生殖系 安全法 

分 类 号：D92[政治法律—法学]